ReviewMedical oncology (Northwood, London, England)2019
Liver graft rejection following immune checkpoint inhibitors treatment: a review.
Review in Medical oncology (Northwood, London, England), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it, 42 citations in OpenAlex.
- Global trends of peripheral immune tolerance research: a bibliometric and visualization analysis.Frontiers in immunology · 2026Pooled it
- Immune checkpoint inhibitors in malignancies after liver transplantation: A systematic review and pooled analysis.Liver international : official journal of the International Association for the Study of the Liver · 2023Pooled it
- Observational
- Nanotechnology-Driven Precision Modulation of Transplant Immunity: From Mechanistic Insights to Clinical Tolerance.International journal of nanomedicine · 2026Review
- Managing hepatocellular carcinoma recurrence after liver transplantation: emerging role of immune checkpoint inhibitors.Discover oncology · 2025Review
- Immunotherapy and Liver Transplantation: A Narrative Review of Basic and Clinical Data.Cancers · 2023Review
- Immunotherapy for hepatocellular carcinoma recurrence after liver transplantation, can we harness the power of immune checkpoint inhibitors?Frontiers in immunology · 2023Review
- An immune and epigenetics-related scoring model and drug candidate prediction for hepatic carcinogenesis via dynamic network biomarker analysis and connectivity mapping.Computational and structural biotechnology journal · 2023Article
- Advances and effectiveness of the immunotherapy after liver transplantation.World journal of gastrointestinal surgery · 2022Article
- Development and verification of the glycolysis-associated and immune-related prognosis signature for hepatocellular carcinoma.Frontiers in genetics · 2022Article
- Transcriptomic analysis of graft liver provides insight into the immune response of rat liver transplantation.Frontiers in immunology · 2022Article
- A novel tumor doubling time-related immune gene signature for prognosis prediction in hepatocellular carcinoma.Cancer cell international · 2021Article
- Nephrotoxicity of cancer therapeutic drugs: Focusing on novel agents.Kidney research and clinical practice · 2021Article
- Immunotherapy use outside clinical trial populations: never say never?Annals of oncology : official journal of the European Society for Medical Oncology · 2021Review
- Construction of a lipid metabolism-related and immune-associated prognostic signature for hepatocellular carcinoma.Cancer medicine · 2020Article
- The roles of mutated SWI/SNF complexes in the initiation and development of hepatocellular carcinoma and its regulatory effect on the immune system: A review.Cell proliferation · 2020Review
- Development and Verification of the Hypoxia-Related and Immune-Associated Prognosis Signature for Hepatocellular Carcinoma.Journal of hepatocellular carcinoma · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Immune checkpoint inhibitors (ICIs) have demonstrated remarkable efficacy in a variety of solid tumors; nonetheless, they have not been well investigated and are still recognized as a relative contraindication for patients with a liver transplantation (LT) history, since ICIs treatment might potentially lead to graft rejection. The program death-1 (PD-1) and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) pathways are implicated in the tolerance of transplanted organ, as well as blockade of the pathways, which contribute to eliminating tumors and may inadvertently lead to peripheral transplant rejection. Currently, no guidelines are available regarding the treatment for ICIs patients with a prior LT history. Therefore, this study was carried out to review the recent studies, attempting to introduce the ICIs-related graft rejection after LT from various aspects. We believed that ICIs could be given for the well-informed patients receiving LT and developed recurrence in a controlled setting. Typically, these patients should be treated according to a clinical care path or a prospective clinical trial, so as obtain a persistent anti-tumor immune response in the meantime of avoiding graft rejection, adjust the immunosuppression, reduce the possibility of graft loss following rejection, and have the opportunity to develop biomarkers for tumor response and transplant rejection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.